Company History
LinqMed Inc., a certified venture company of the National Institutes for Quantum Sciences and Technology (QST), is a start-up radiopharmaceutical company to provide innovative “visible” anti-cancer drugs to patients. Formed on July 4th, 2022, our clinical focus is exclusively on cancer, especially, neuro-oncology and pancreatic cancer.
| 2018, July | The National Institutes for Quantum Science and Technology (QST) initiated an investigator-sponsored Phase I clinical trial for recurrent and refractory malignant brain tumors. This was the world’s first-in-human trial of ⁶⁴Cu for therapeutic use. |
|---|---|
| 2022, July | LinqMed Inc. was founded and established in Chiba City, as a certified QST venture company. |
| 2023, December | LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan |
| 2023, December | LinqMed closed its Series A financing round, raising JPY 930 million. |
| 2024, January | LinqMed established a Social Cooperation Program at the University of Tokyo’s Radioisotope Center. |
| 2024, February | LinqMed’s development program for the radiotherapeutic agent ⁶⁴Cu-ATSM for recurrent and refractory malignant glioma was selected for AMED’s “Practical Application Support Program for Orphan Drugs Prior to Designation.” |
| 2024, June | LinqMed confirmed the safety and efficacy of ⁶⁴Cu-ATSM, a novel Japanese-origin radiotherapeutic agent for recurrent and refractory malignant brain tumors, and initiated a Phase III comparative trial in malignant glioma toward regulatory approval. |
| 2023, December | Announcement of selection for NEDO “The Deep-Tech Startup Support Fund/Deep-Tech Startup Support Program” |
| 2024, June | Phase I Investigator-Initiated Trial Begins for PET Imaging of Pancreatic Cancer Using EUS-Guided Radiolabeled Antibody Administration |
| 2024, August | LinqMed received the Special Award at the University Venture Awards 2024. |
| 2025, May | LinqMed closed its Series B financing round, raising JPY 3.85 billion. |
| 2025, October | LinqMed relocated its headquarters to Midori-ku, Chiba City. |
| 2025, November | LinqMed completed construction of its Chiba manufacturing facility in Midori-ku, Chiba City. |
| 2025, December | Demonstration of the Efficacy of Hypoxia-Targeted Local Radiotherapy for Malignant Brain Tumors |
| 2026, January | LinqMed was selected as a tenant of Japan Innovation Campus, a business hub established by Japan’s Ministry of Economy, Trade and Industry in Silicon Valley, United States. |
| 2026, May | LinqMed’s development program for ⁶⁴Cu-ATSM, a hypoxia-targeted theranostic radiopharmaceutical in combination with chemoradiotherapy for patients with unresectable locally advanced head and neck cancer, was selected for AMED’s “Translational Research Program.” |
| 2026, July | Phase I Clinical Trial Results of ⁶⁴Cu-ATSM Radioligand Therapy for Recurrent Malignant Brain Tumors Published in ESMO Open, a Peer-Reviewed Journal |